{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:53:58Z","timestamp":1794020038961,"version":"4.8.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Niemann\u2013Pick disease type C (NP-C) is a rare autosomal recessive lysosomal storage disorder characterized by progressive neurodegeneration. This study aimed to characterize the clinical features and treatment outcomes of NP-C in Iranian patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted a cross-sectional study of 58 patients with NP-C diagnosed between March 2013 and March 2024 at Mofid Children\u2019s Hospital, Tehran. Clinical manifestations were categorized into visceral, cortical, and deep brain domains. Treatment outcomes were assessed in 52 patients who received miglustat therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The mean age at disease onset was 3.35\u2009\u00b1\u20093.40 years, with diagnosis occurring at 7.03\u2009\u00b1\u20094.60 years. Filipin staining confirmed diagnosis in 96.6% of cases. Following miglustat therapy (mean duration: 1.96\u2009\u00b1\u20092.54 years), 86.5% of patients remained stable or showed improvement in at least one disease domain. Visceral manifestations showed the most favorable response, with 30.8% of patients demonstrating improvement in hepatosplenomegaly. Cortical manifestations (seizures and cognitive disorders) improved in 13.5% of patients. Motor function remained stable in 63.5% of patients, while 7.7% experienced deterioration. Ocular manifestations remained largely stable (94.2%). Seven patients (13.5%) experienced deterioration in at least one domain. At study completion, mortality was 20.7%, with mean age at death of 11.58\u2009\u00b1\u20097.73 years.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This first comprehensive analysis of NP-C in Iran demonstrates the effectiveness of miglustat across multiple disease manifestations, particularly for visceral and cortical symptoms. While neurological symptoms generally stabilized, responses varied, emphasizing the need for individualized therapeutic approaches. Early diagnosis and intervention remain crucial for improving outcomes in this progressive neurodegenerative disorder.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03897-9","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:49:59Z","timestamp":1756291799000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical characteristics and treatment outcomes in patients with Niemann\u2013Pick disease type C (NP-C): a cross-sectional study"],"prefix":"10.1186","volume":"20","author":[{"given":"Parvaneh","family":"Karimzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzad","family":"Ahmadabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahide","family":"Zeinali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharareh","family":"Kamfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Reza","family":"Ashrafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Reza","family":"Tavasoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Hassan","family":"Tonekaboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2154-6704","authenticated-orcid":false,"given":"Faezeh","family":"Ghanaati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"issue":"1\u20132","key":"3897_CR1","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ymgme.2021.06.011","volume":"134","author":"BK Burton","year":"2021","unstructured":"Burton BK, Ellis AG, Orr B, Chatlani S, Yoon K, Shoaff JR, Gallo D. Estimating the prevalence of Niemann-Pick disease type C (NPC) in the United States. Mol Genet Metab. 2021;134(1\u20132):182\u20137.","journal-title":"Mol Genet Metab"},{"key":"3897_CR2","doi-asserted-by":"crossref","unstructured":"Berry-Kravis E: Niemann-Pick disease, type C: diagnosis, management and disease-targeted therapies in development. In: Seminars in Pediatric Neurology: 2021: Elsevier; 2021: 100879.","DOI":"10.1016\/j.spen.2021.100879"},{"issue":"22","key":"3897_CR3","doi-asserted-by":"publisher","first-page":"20917","DOI":"10.1074\/jbc.R400040200","volume":"280","author":"TY Chang","year":"2005","unstructured":"Chang TY, Reid PC, Sugii S, Ohgami N, Cruz JC, Chang CC. Niemann-Pick type C disease and intracellular cholesterol trafficking. J Biol Chem. 2005;280(22):20917\u201320.","journal-title":"J Biol Chem"},{"issue":"1","key":"3897_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13023-018-0785-7","volume":"13","author":"T Geberhiwot","year":"2018","unstructured":"Geberhiwot T, Moro A, Dardis A, Ramaswami U, Sirrs S, Marfa MP, Vanier MT, Walterfang M, Bolton S, Dawson C, H\u00e9ron B. Consensus clinical management guidelines for Niemann-Pick disease type C. Orphanet J Rare Dis. 2018;13(1):50.","journal-title":"Orphanet J Rare Dis"},{"key":"3897_CR5","doi-asserted-by":"crossref","unstructured":"Vanier MTJOjord: Niemann-Pick disease type C. 2010, 5:1\u201318.","DOI":"10.1186\/1750-1172-5-16"},{"key":"3897_CR6","doi-asserted-by":"crossref","unstructured":"Mishra S, Kell P, Scherrer D, Dietzen DJ, Vite CH, Berry-Kravis E, Davidson C, Cologna SM, Porter FD, Ory DS, Jiang X. Accumulation of alkyl-lysophosphatidylcholines in Niemann-Pick disease type C1. J Lipid Res. 2024;65(8).","DOI":"10.1016\/j.jlr.2024.100600"},{"issue":"1","key":"3897_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1750-1172-8-12","volume":"8","author":"MC Patterson","year":"2013","unstructured":"Patterson MC, Mengel E, Wijburg FA, Muller A, Schwierin B, Drevon H, Vanier MT, Pineda M. Disease and patient characteristics in NP-C patients: findings from an international disease registry. Orphanet J Rare Dis. 2013;8(1):12.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3897_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13023-022-02200-4","volume":"17","author":"SC Bolton","year":"2022","unstructured":"Bolton SC, Soran V, Marfa MP, Imrie J, Gissen P, Jahnova H, Sharma R, Jones S, Santra S, Crushell E, Stampfer M. Clinical disease characteristics of patients with Niemann-Pick disease type C: findings from the International Niemann-Pick disease registry (INPDR). Orphanet J Rare Dis. 2022;17(1):51.","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"3897_CR9","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1007\/s10072-021-05337-5","volume":"42","author":"G Maresca","year":"2021","unstructured":"Maresca G, Formica C, Nocito V, Latella D, Leonardi S, De Cola MC, Triglia G, Bramanti P, Corallo F. Neuropsychological assessment in Niemann-Pick disease type C: a systematic review. Neurol Sci. 2021;42(8):3167\u201375.","journal-title":"Neurol Sci"},{"key":"3897_CR10","doi-asserted-by":"crossref","unstructured":"Ong LTJPG: Psychosis symptoms associated with Niemann-Pick disease type C. 2021; 31(4):107\u2013118.","DOI":"10.1097\/YPG.0000000000000286"},{"issue":"14","key":"3897_CR11","doi-asserted-by":"publisher","first-page":"5059","DOI":"10.3390\/ijms21145059","volume":"21","author":"B Seker Yilmaz","year":"2020","unstructured":"Seker Yilmaz B, Baruteau J, Rahim AA, Gissen P. Clinical and molecular features of early infantile Niemann Pick type C disease. Int J Mol Sci. 2020;21(14):5059.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3897_CR12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13023-020-01363-2","volume":"15","author":"MC Patterson","year":"2020","unstructured":"Patterson MC, Mengel E, Vanier MT, Moneuse P, Rosenberg D, Pineda M. Treatment outcomes following continuous miglustat therapy in patients with Niemann-Pick disease Type C: a final report of the NPC Registry. Orphanet J Rare Dis. 2020;15(1):104.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"3897_CR13","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1007\/s11096-022-01491-8","volume":"44","author":"M Guti\u0107","year":"2022","unstructured":"Guti\u0107 M, Milosavljevi\u0107 MN, Jankovi\u0107 SM. Cost-effectiveness of miglustat versus symptomatic therapy of Niemann-Pick disease type C. Int J Clin Pharm. 2022;44(6):1442\u201353.","journal-title":"Int J Clin Pharm"},{"issue":"12","key":"3897_CR14","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1177\/0883073812464526","volume":"28","author":"P Karimzadeh","year":"2013","unstructured":"Karimzadeh P, Tonekaboni SH, Ashrafi MR, Shafeghati Y, Rezayi A, Salehpour S, Ghofrani M, Taghdiri MM, Rahmanifar A, Zaman T, Aryani O. Effects of miglustat on stabilization of neurological disorder in Niemann-Pick disease type C: Iranian pediatric case series. J Child Neurol. 2013;28(12):1599\u2013606.","journal-title":"J Child Neurol"},{"issue":"1","key":"3897_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1750-1172-8-35","volume":"8","author":"M Stampfer","year":"2013","unstructured":"Stampfer M, Theiss S, Amraoui Y, Jiang X, Keller S, Ory DS, Mengel E, Fischer C, Runz H. Niemann-Pick disease type C clinical database: cognitive and coordination deficits are early disease indicators. Orphanet J Rare Dis. 2013;8(1):35.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"3897_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1192\/pb.bp.116.054072","volume":"41","author":"WR Evans","year":"2017","unstructured":"Evans WR, Hendriksz CJ. Niemann-Pick type C disease\u2013the tip of the iceberg? a review of neuropsychiatric presentation, diagnosis and treatment. BJPsych Bullet. 2017;41(2):109\u201314.","journal-title":"BJPsych Bullet"},{"issue":"1","key":"3897_CR17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13023-023-02741-2","volume":"18","author":"E Golden","year":"2023","unstructured":"Golden E, van Gool R, Cay M, Goodlett B, Cao A, Al-Hertani W, Upadhyay J. The experience of living with Niemann-Pick type C: a patient and caregiver perspective. Orphanet J Rare Dis. 2023;18(1):120.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"3897_CR18","doi-asserted-by":"publisher","first-page":"146","DOI":"10.37349\/ent.2021.00012","volume":"1","author":"X Jiang","year":"2021","unstructured":"Jiang X, Ory DS. Advancing diagnosis and treatment of Niemann-Pick C disease through biomarker discovery. Expl Neuroprotect Ther. 2021;1(3):146.","journal-title":"Expl Neuroprotect Ther"},{"issue":"3","key":"3897_CR19","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1590\/0004-282X20130249","volume":"72","author":"PJ Lorenzoni","year":"2014","unstructured":"Lorenzoni PJ, Cardoso E, Crippa AC, Louren\u00e7o CM, Souza FT, Giugliani R, Saraiva-Pereira ML, Raskin S, Bruck I, Kay CS, Scola RH. Niemann-Pick disease type C: a case series of Brazilian patients. Arq Neuropsiquiatr. 2014;72(3):214\u20138.","journal-title":"Arq Neuropsiquiatr"},{"issue":"1","key":"3897_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13023-019-0996-6","volume":"14","author":"M Pineda","year":"2019","unstructured":"Pineda M, Jur\u00ed\u010dkov\u00e1 K, Karimzadeh P, Kolnikova M, Malinova V, Insua JL, Velten C, Kolb SA. Disease characteristics, prognosis and miglustat treatment effects on disease progression in patients with Niemann-Pick disease type C: an international, multicenter, retrospective chart review. Orphanet J Rare Dis. 2019;14(1):32.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3897_CR21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s13023-023-02804-4","volume":"18","author":"C Freihuber","year":"2023","unstructured":"Freihuber C, Dahmani-Rabehi B, Brassier A, Brou\u00e9 P, Cances C, Chabrol B, Eyer D, Labarthe F, Latour P, Levade T, et al. Effects of miglustat therapy on neurological disorder and survival in early-infantile Niemann-Pick disease type C: a national French retrospective study. Orphanet J Rare Dis. 2023;18(1):204.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"3897_CR22","doi-asserted-by":"publisher","first-page":"227","DOI":"10.5582\/irdr.2024.01056","volume":"13","author":"H Zhang","year":"2024","unstructured":"Zhang H, Xiong H, Wei C, Yi M, Che Y, Zhuo J, Li X. Evaluation of the safety and efficacy of miglustat for the treatment of Chinese patients with Niemann-Pick disease type C: a prospective, open-label, single-arm, phase IV trial. Intract Rare Dis Res. 2024;13(4):227\u201335.","journal-title":"Intract Rare Dis Res"},{"key":"3897_CR23","first-page":"100739","volume":"27","author":"S Curelaru","year":"2021","unstructured":"Curelaru S, Zehavi Y, Almagor T, Spiegel R. Favorable outcomes following early onset oral miglustat in early infantile Niemann Pick Type C. Mol Genet Metab Rep. 2021;27:100739.","journal-title":"Mol Genet Metab Rep"},{"issue":"3","key":"3897_CR24","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1007\/s00415-021-10717-0","volume":"269","author":"T Bremova-Ertl","year":"2022","unstructured":"Bremova-Ertl T, Claassen J, Foltan T, Gascon-Bayarri J, Gissen P, Hahn A, Hassan A, Hennig A, Jones SA, Kolnikova M, Martakis K. Efficacy and safety of N-acetyl-l-leucine in Niemann-Pick disease type C. J Neurol. 2022;269(3):1651\u201362.","journal-title":"J Neurol"},{"issue":"5","key":"3897_CR25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.braindev.2024.03.002","volume":"46","author":"M Matsuo","year":"2024","unstructured":"Matsuo M, Sakakibara T, Sakiyama Y, So T, Kosuga M, Kakiuchi T, Ichinose F, Nakamura T, Ishitsuka Y, Irie T. Long-term efficacy of intrathecal cyclodextrin in patients with Niemann-Pick disease type C. Brain Dev. 2024;46(5):207\u201312.","journal-title":"Brain Dev"},{"issue":"6","key":"3897_CR26","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/jimd.12428","volume":"44","author":"E Mengel","year":"2021","unstructured":"Mengel E, Patterson MC, Da Riol RM, Del Toro M, Deodato F, Gautschi M, Grunewald S, Gr\u00f8nborg S, Harmatz P, H\u00e9ron B, Maier EM. Efficacy and safety of arimoclomol in Niemann-Pick disease type C: results from a double-blind, randomised, placebo-controlled, multinational phase 2\/3 trial of a novel treatment. J Inherit Metab Dis. 2021;44(6):1463\u201380.","journal-title":"J Inherit Metab Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03897-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03897-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03897-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T18:39:43Z","timestamp":1757443183000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03897-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3897"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03897-9","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"assertion":[{"value":"15 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all patients or their legal guardians.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors confirm that there are no conflicts of interest related to this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"459"}}